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Abstract The role of vascular endothelium in cardiovas-
cular disorders is well recognized. Mature endothelial cells
contribute to the repair of endothelial injury, but they only
have a limited capacity to do so. This has led to growing
interest and further investigation into circulating endothelial
progenitor cells (EPCs) and their role in vascular healing,
repair, and postnatal neovascularization. The current per-
ception of vascular health is that of a balance between
ongoing injury and resultant vascular repair, mediated at
least in part by circulating EPCs. Circulating EPCs play an
important role in accelerating endothelialization at areas of
vascular damage, and EPC enumeration is a viable strategy
for assessing reparative capacity. Recent studies have
shown that EPCs are affected both in number and function
by several cardiovascular risk factors as well as various
cardiovascular disease states, such as hypertension, hyper-
cholesterolemia, and coronary artery disease. The present
review summarizes the most relevant studies on the effects
of cardiovascular drugs on vascular function and EPCs,
focusing on their mechanisms of action.
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Introduction
Endothelial dysfunction, atherosclerosis and cardiovascular
disease
Atherosclerosis is a progressive and complex disease,
characterized by thickening of the arterial wall, with focal
complications in different vascular beds [1]. Risk factors
and a genetic predisposition together seem to induce
inflammatory processes that lead to cell damage and impair
regeneration within the vessel wall [2]. However, despite
intense efforts to determine the pathogenesis of atheroscle-
rosis, this process remains poorly understood.
Several experimental and clinical studies have demon-
strated that the endothelium, situated at the interface
between blood flow and the vascular wall, plays a crucial
role in the regulation of vascular tone and structure [1, 3].
For several years, the endothelial monolayer had been
considered to be a simple barrier. It has become evident,
however, that the endothelium is a complex organ, with
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paracrine and autocrine function, which provides a “first
line” physiological defense against atherosclerosis [4]. A
healthy endothelium is now considered to be a major
regular of vascular homeostasis, regulating the vascular
tone and structure and paying a key role in angiogenesis
and inflammation.
Endothelial dysfunction is an early event in the patho-
genesis of atherosclerosis. Mechanisms that can contribute
to endothelial dysfunction are oxidative stress, upregulation
of adhesion molecules, increase in the inflammatory
response and protrombotic state. Vasoactive peptides, such
as angiotensin II and endothelin-1, hypercholesterolemia,
hyperhomocysteinemia, and hyperglycemia may participate
in these mechanisms. Apoptosis of endothelial cells can
also be implicated in endothelial dysfunction [5].
Oxidative stress can inhibit the three major endothelium-
dependent vasodilator pathways, i.e., nitric oxide (NO),
prostacyclin, and endothelium-derived hyperpolarizing fac-
tor and seems to be a first alteration responsible for
triggering endothelial dysfunction in cardiovascular dis-
eases. The reduced bioavailability of NO, the impairment in
prostanoid synthesis, including prostacyclin, thromboxane
A2, and/or isoprostanes, as well as the increased release of
endothelin-1 can individually or in association contribute to
the initiation and progression of the impairment of
endothelial function [6].
A recently discovered pathway of prostacyclin signaling
involves the activation of peroxisome proliferator-activated
receptors (PPARs). These receptors seem to have very
important roles in the beneficial endothelial effects of
prostacyclin. In fact, this endothelium-derived vasodilator
seems to have angiogenic properties that are dependent on
its specific action on the PPAR signaling pathway [7].
Nitric oxide is a pivotal endothelium-derived substance.
It is synthesized from the substrate L-arginine via endothe-
lial NO synthase (eNOS) and plays a crucial role in
vasorelaxation, inhibition of leukocyte-endothelial adhe-
sion, vascular smooth muscle cell migration and prolifera-
tion, and platelet aggregation [8]. A defect in NO
production or its activity has been proposed as a major
mechanism of endothelial dysfunction, thus contributing to
atherosclerosis [9].
A growing body of evidence shows that deregulation of
the endothelial NO pathway, which can cause endothelial
dysfunction, is not only associated with all major cardio-
vascular risk factors, such as hypercholesterolemia, diabe-
tes, hypertension, and smoking, but that it also has a
profound predictive value for future atherosclerotic disease
progression [10, 11]. Therefore, the dysfunctional eNOS/
NO pathway is considered to be a hallmark of endothelial
dysfunction [9].
Despite experimental evidence demonstrating the contri-
bution of endothelial eNOS/NO impairment in the patho-
genesis of atherosclerosis, no single underlying mechanism
can fully explain endothelial dysfunction. This may simply
be due to the fact that atherosclerosis is a complex disease
process and that multiple regulatory mechanisms are
involved in endothelial NO bioactivity.
Endothelial progenitor cells and vascular repair
Circulating endothelial progenitor cells (EPCs) derived
from bone marrow were isolated for the first time in 1997
[12]. Following the publication of this initial report by
Asahara et al., growing interest has focused on gaining an
understanding of the mobilization, homing, and function of
EPCs under several conditions and also on its potential as a
new strategy in regenerative medicine.
Bone marrow-derived EPCs contribute to the re-
endothelialization of injured vessels and ischemia-induced
neovascularization, and they improve endothelial function
[13, 14]. Therefore, circulating EPCs may represent an
important endogenous repair mechanism by which the
body maintains the integrity of the endothelium mono-
layer [12, 15, 16]. Several clinical studies have shown that
the number and function of EPCs are impaired in some
pathological conditions. These findings suggest that it could
be very important to estimate EPCs levels and to increase
their bioactivity by appropriate interventions [13].
EPCs can be mobilized into the circulation in response to
angiogenic growth factors, chemokines, and cytokines
released following various stimuli, such as vascular trauma
[17]. Granulocyte macrophage-colony stimulating factor
(GM-CSF) seems to amplify EPC mobilization, recruiting
them into the site of new blood vessel formation in severely
ischemic tissues [18]. Hypoxia-inducible factor-1 (HIF-1), a
central transcriptional regulator of hypoxia-specific gene
expression, induces the expression of signaling factors,
such as stromal-derived factor (SDF-1) and vascular
endothelial growth factor (VEGF), in EPCs or the endothe-
lium and facilitates adhesion of these progenitor cells to the
ischemic endothelium [19]. SDF-1, also known as
CXCL12, through interaction with its receptor CXCR4
(also known as CD184), modulates angiogenesis as well as
hematopoiesis [2].
Of note, EPCs are believed to exert their function by two
main strategies: activating locally the endothelial cells
and/or differentiating into mature endothelial cells that
integrate the damaged vessels. To do this, EPCs must
home to “angiogenic active” sites and then adhere to the
activated/damaged endothelial cells or to the extracellular
matrix, thereby contributing to the endothelial repair
process [20].
Recent clinical evidence supports the concept that
several cardiovascular risk factors (hypertension, diabetes,
hypercholesterolemia, and smoking) as well as various
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cardiovascular diseases are associated with EPC impair-
ment, both in number and function [21]. Moreover, reduced
EPC levels seem to be correlated with endothelial dysfunc-
tion and with an increased risk of cardiovascular events,
compatible with the concept that impaired EPC-mediated
vascular repair promotes the progression of vascular disease
[22]. Importantly, it has been suggested that reduced levels
of circulating EPCs represent a cellular marker that
independently predicts outcome in patients with vascular
disease, and the level of circulating EPCs has been
proposed as a surrogate index of cumulative cardiovascular
risk [2].
At the present time, EPC quantification is largely
performed by two methods: (1) fluorescence-activated cell
sorting (FACS) analysis of total blood cells or circulating
mononuclear cells and (2) culture assay of blood-derived
mononuclear cells. Circulating EPCs are characterized by
the expression of CD133, CD34, and vascular endothelial
growth factor receptor-2 (VEGFR2) [23]. Therefore, they
can be identified and quantified based on the expression of
these cell surface markers. In several studies, the marker
combinations of CD34+KDR+, CD34+CD133+, and
CD34+CD133+KDR+ have been the most frequently used
markers for identifying human EPCs [24, 25].
It would be very interesting to develop pharmacological
approaches that promote vascular repair and prevent
endothelial cell apoptosis, thereby protecting the structural
and functional integrity of the endothelium. Thus, within
the context of promoting the health of the vascular system,
it would be very beneficial to identify pharmacological
interventions that could increase circulating EPCs levels
and improve their bioactivity.
Stimulation of EPCs: a new putative effect of several
cardiovascular drugs
Both experimental and human studies have demonstrated
that the number of functionally active EPCs is regulated not
only by various angiogenic cytokines and cardiovascular risk
factors, but also by some interventions, including lifestyle
modification (aerobic exercise, body weight loss, and
smoking cessation) and by pharmacological intervention
[15, 26].
EPCs exist in very small numbers, especially in the
circulating blood of adults, where they only account for
approximately 0.01% of all cells [17].
Several experimental and even clinical studies have
demonstrated the impact of various pharmacological agents
on the number and function of EPCs (Table 1). This impact
could be of therapeutic relevance because persistent
stimulation of EPCs by targeted pharmacological interven-
tion could, at least theoretically, repair endothelial injury
and prevent progression of atherosclerotic vascular disease
in patients at risk.
In this review we summarize recent data on the effects of
cardiovascular drugs on mobilization and functional activ-
ity of EPCs, with an attempt to focus on the mechanisms of
action involved.
Table 1 Cardiovascular drugs with potential positive effects on EPCs
Cardiovascular drugs Effects on EPCs and potential
mechanisms of action
Lipid-lowering drugs
Statins Improvement in proliferation,
differentiation, migratory function
of EPCs (important role of eNOS)
Delay of EPCs senescence (via the Akt
signaling pathway)
Increasing of EPC homing (through the
upregulation of endothelial integrin






Renin–angiotensin-aldosterone system active agents
Spironolactone Attenuation of the inhibitory effect
of aldosterone on EPC formation by
aldosterone (via the Akt signaling
pathway)
ACE-Inhibitors Improvement in EPC mobilization
(by increasing circulating SDF-1α








Increase in number of circulating










Induction of EPC mobilization and
increase in number of circulating
EPCs (via the PI3K/Akt signaling
pathway and the antioxidant system)benidipine
nisoldipine
nifedipine
Beta blockers Increase in the number of circulating
EPCs (via inhibition of oxidative
stress in EPCs)
celiprolol
Nitrates Increase in level of circulating EPCs
(by release of NO)nitroglycerine
Aspirin (in a low dose) Promotion of EPC migration and
adhesion (?)
Delay of EPC senescence (?)
EPCs Endothelial progenitor cells; eNOS, endothelial nitric oxide
synthase; ACE-inhibitors, angiotensin-converting enzyme inhibitors;
SDF, stromal-derived factor; PI3K, phosphatidylinositol 3-kinase; NO,
nitric oxide
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Statins
Endothelial dysfunction is frequently seen in hypercholes-
terolemic patients [3]. Unfortunately, a growing body of
evidence indicates that hypercholesterolemia not only
exerts a direct harmful effect on the endothelium but also
indirectly reduces both the availability and functionality of
EPCs, thus limiting EPC-mediated vascular repair [27].
Low-density lipoproteins (LDLs) play an active role in
the onset and progression of atherosclerosis [28]. The
impairment of endothelium-dependent vascular relaxation
secondary to a decrease in NO bioavailability is one of the
early deleterious effects produced by high plasma levels of
LDLs [29]. It has also been shown that chronic hypercho-
lesterolemia favors a proapoptotic status of vascular
endothelial cells. The mechanism responsible for this effect
has been extensively analyzed and seems to be mediated by
reactive oxygen species (ROS) [30, 31].
The effectiveness of different 3-hydroxy-3-methylglu-
taryl coenzyme A (HMG-CoA) reductase inhibitors (sta-
tins) to reduce cholesterol levels and prevent cardiovascular
morbidity and mortality has been consistently demonstrated
[29]. A more recent development has been the demonstra-
tion that statins also exert benefits not related to the
reduction of cholesterol levels; these are known as
pleiotropic effects [32]. In addition to their lipid-lowering
property, statins are also able to reduce vascular inflammation
[33], decrease platelet aggregation and thrombus deposition
[34], and increase endothelium-derived NO production [35].
Thus, although statins were initially designed to lower LDL-
cholesterol levels, they have become established drugs in the
treatment of coronary artery disease (CAD) even in patients
with normal LDL levels, due to their pleiotropic effects [32].
In fact, increasing evidence supports profound, positive
effects of statins on endothelial cell function through both
cholesterol-dependent and cholesterol-independent effects
[36, 37].
It is widely recognized that statins increase NO
production by several mechanisms, including the upregula-
tion of eNOS mRNA and protein levels and the restoration
of eNOS activity reduced by oxLDLs or atherogenic native
LDLs [38, 39]. Moreover, recent studies have shown that
statins also exert a beneficial effect on angiogenesis and
EPC bioactivity, both mechanisms that could also be
associated with the significant improvement of endothelial
function produced by these drugs [25, 29, 40, 41].
Therefore, augmentation of circulating EPCs by statin
therapy may significantly contribute to the stimulation of
neovascularization that follows tissue ischemia.
Previous data suggest that the modulation of EPC
kinetics after statin treatment is unrelated to the decrease
in serum LDL-cholesterol levels [25]. Landemesser et al.
have demonstrated that similar reductions in LDL-
cholesterol with simvastatin and ezetimibe in patients with
chronic heart failure resulted in different effects on
endothelial function and EPCs. There was a marked
increase in functionally active EPCs after 4 weeks of statin
treatment, whereas ezetimibe therapy had no effect on
EPCs [42]. However, the exact mechanisms behind these
serum lipid-independent effects of statins on EPCs kinetics
are still not well understood.
Statin therapy and angiogenesis: mechanisms of action
Several clinical studies have clearly shown that statin
therapy improves angiogenesis and EPC bioactivity. Here,
we present the most relevant data on these effects and
discuss the potential intracellular mechanisms involved.
Accumulating evidence suggests that several statins
(rosuvastatin [43], simvastatin [42, 44, 45], atorvastatin
[25, 46–48], fluvastatin [49], and cerivastatin [50]) mobilize
EPCs, induce proliferation and differentiation, improve
migratory function, have anti-apoptotic effects over EPCs,
and increase EPC homing. However, studies with pravastatin
have suggested that this statin is not as efficient as others in
improving the number and function of EPCs [46, 51]. This
observation, however, should be further investigated.
Several experiments establish a novel role for statins,
analogous to that described for EPC-modulating cytokines,
in the regulation of postnatal neovascularization [25, 41].
Statins seem to be a major stimuli for bone marrow-derived
EPCs mobilization, thus improving vasculogenesis and re-
endothelization [25, 41]. This effect on EPC activity may
represent a novel pleiotropic effect of statin therapy [52].
There is increasing evidence for statin treatment increas-
ing the number of circulating EPCs, based on FACS
detection of CD34+/KDR+ cells or as assessed in vitro by
culture assays of early EPCs. Vasa et al. showed that
atorvastatin increased the number of circulating EPCs in
patients with stable CAD. Moreover, this effect was as early
as 1 week after the initiation of atorvastatin therapy and had
risen to approximately threefold at 3–4 weeks after its
introduction [25].
Dimmeler et al. demonstrated that the increase in the
number of EPCs by atorvastatin is at least equipotent as the
prototypic angiogenic cytokine VEGF, which is known to
promote EPC mobilization and differentiation [40]. These
researchers concluded that it was unlikely that the effects of
statins were mediated via the upregulation of angiogenic
growth factors. It would appear that statins augment
circulating levels of bone marrow hematopoietic precursor
cells and directly induce the differentiation of these
precursor cells into EPCs. Thus, statins may influence not
only the mobilization of hematopoietic progenitor cells, as
has been shown for VEGF, but they may also modulate
differentiation [40].
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The effects of statins on eNOS appear to be critical for
EPC mobilization and proliferation. Landmesser et al.
showed a marked improvement in EPC mobilization and
myocardial neovascularization after atorvastatin treatment
in wild-type mice, while it had no effect in eNOS-deficient
mice (eNOS−/−) [47]. Furthermore, in wild-type animals
treated with cerivastatin, the inhibition of eNOS by nitro-L-
arginine-methyl ester prevented the formation of angiotubes
and collateral growth in response to ischemia, suggesting
that eNOS is essential for statin to be able to enhance blood
flow recovery after ischemia [50, 53].
Accumulating evidence suggests that EPCs treated with
statins not only show an increased ability to form colonies
and to improve proliferation [41, 54], but also demonstrate
enhanced migratory capacity [25, 41, 48].
With respect to the statin-mediated delay of EPC
senescence, the upregulation of the telomere-capping
protein telomere repeat-binding factor TRF2 in EPCs (that
prevents telomerase dysfunction) rather than an increase in
telomere length is now thought to explain how statins
favorably affect senescence in human EPCs [48, 54].
Human telomeres are bound by two double-strand telomere
binding proteins, TRF1 and TRF2. The removal of TRF2
triggers apoptosis or senescence [55]. Premature senescence
of cultured cells can be triggered by oxidative stress,
leading to telomere dysfunction [56, 57]. Recent experi-
mental and clinical evidence supports the possibility that
telomere dysfunction can occur because of the loss of
TRF2, implying a role of telomere “uncapping” rather than
telomere shortening as an explanation for senescence [58,
59]. Spyridopoulos et al. have demonstrated that the delay
of EPC premature senescence produced by statins is
independent of mean telomere length [48]. In this study,
exogenous TRF2 reproduced the statin effect, and a
dominant-interfering mutation blocked this senescence
delay, implicating TRF2 in this process [48]. The beneficial
effects of statins on telomere function have also been
related to ability of statins to enhance the migratory
capacity of EPCs. It is possible that the induction of
TRF2 by statins leads to “juvenation” of EPCs because
replicative senescence is delayed. Therefore, these younger
cells would migrate faster than older cells primarily due to
their age characteristics [48].
There is emerging evidence suggesting that the phos-
phatidylinositol 3-kinase and Akt-dependent signaling
pathway (PI3K/Akt) plays a critical role in statin-induced
neovascularization and improvement in EPC viability [40].
In mature endothelial cells, it has been shown that the
kinase Akt acts downstream of the angiogenic growth
factors VEGF and angiopoietin, promoting endothelial cell
survival [60]. The activation of Akt leads to the inhibition
of endothelial cell apoptosis, stimulates endothelial NO
synthesis, and mediates VEGF-induced endothelial cell
migration [60, 61]. Akt has also been shown to be essential
for EPC migration induced by VEGF and for the
differentiation of EPCs [61]. Moreover, recent studies have
identified Akt as a target for statins in their role as a
modifier of EPC kinetics [40, 44]. It seems that statins
rapidly activate Akt signaling in EPCs, enhance phosphor-
ylation of the endogenous Akt substrate eNOS, inhibit
apoptosis, and accelerate the formation of vascular struc-
tures in vitro in an Akt-dependent manner [41, 44]. Of note,
the promotion of EPC proliferation, migration, and cell
survival in vitro via the Akt signaling pathway by statins
has been confirmed by functional blocking with dominant-
negative Akt overexpression [41].
Finally, the increased adhesiveness towards endothelial
cells reported in statin-treated EPCs, which could increase
EPC homing at sites of vascular injury, seems to rely on the
upregulation of endothelial integrin subunits α5, β1, αv
and β5 [45].
In conclusion, multiple studies support that the improve-
ment of EPC functions and neovascularization promoted by
statins could contribute to the clinical benefit of these drugs
and that these effects are—at least in part—independent of
their lipid-lowering properties. However, several questions
remain unanswered and warrant further investigation:
Which mechanisms are involved in the release of EPCs
by statin treatment? Is this release caused by enhanced
proliferation and differentiation of committed stem cells
within the bone marrow, or is it due to an increased release
of a preexisting pool? What are the exact mechanisms
governing these events? What makes endothelial cells attach
to the injured vessel wall? How is this modulated by statins?
In fact, despite intense efforts to determine the exact
mechanisms whereby statins improve EPCs function, their
mechanism of action remains poorly understood.
Renin–angiotensin–aldosterone system active agents
The renin–angiotensin system (RAS) [41] is a circulating
hormonal system that regulates blood pressure and flow. It
is recognized that angiotensin II (Ang II) contributes to the
development of atherosclerosis and promotes cardiovascu-
lar remodeling through its induction of cardiac hypertrophy,
inflammation, apoptosis, and fibrosis through its action on
the angiotensin type 1 receptor (AT1) [62]. Furthermore,
AT1-receptor activation causes superoxide radical release via
the NAPDH oxidase pathway, thereby increasing oxidative
stress in the vascular wall, which leads to endothelial
dysfunction [62, 63]. In contrast, angiotensin type 2 receptors
(AT2) promote vasodilatation and are responsible for
antifibrotic, anti-apoptotic, and anti-inflammatory effects
[64].
AT2 receptors are highly expressed in the developing
fetus, but they decline rapidly after birth. In the adult, the
Eur J Clin Pharmacol (2010) 66:219–230 223
AT2-receptor is predominantly expressed in the brain and
adrenals, being expressed in lower levels elsewhere.
Therefore, angiotensin-dependent functions are primarily
the result of AT1-receptor activation and, to a lesser extent,
AT2-receptor activation [63]. Further research to assess the
potential clinical benefits of specifically targeting the AT2-
receptor could be of great value.
Ang II is formed by the activation of a cascade of
enzymatic conversions from angiotensin I by angiotensin
converting enzyme (ACE). Alternative proteases are pres-
ent in the human heart (e.g., chymase), which produce Ang
II independently of ACE [65]. ACE-inhibitors reduce the
formation of Ang II and lead to the accumulation of NO
and bradykinin [64]. The reduced stimulation of both AT1-
and AT2-receptors is partially offset by an increase in AT1-
receptor stimulation of the Ang II formed by the alternative
pathway, potentially contributing to the “angiotensin escape
phenomenon” observed in patients on chronic ACE-
inhibitor treatment [64].
Recent evidence suggests that other angiotensin peptide
fragments, including Ang-(1–7) and Ang-(3–8) (known as
Ang IV), may bind to non-AT1 receptor subtypes [e.g.,
AT2, AT4, and Ang (1–7)/mas receptor] to counter-regulate
the effects mediated via the AT1. Ang-(1–7) is formed
directly from Ang I via the action of several tissue-specific
endopeptidases or from Ang II via ACE. It interacts with
the G-protein-coupled receptor mas and opposes the actions
of Ang II by stimulating the release of prostacyclin and NO
[67].
The Ang II metabolite, Ang IV, preferentially binds to
a novel angiotensin binding site, which shows a poor
affinity for Ang II (the AT4-receptor). A growing list of
physiological functions has been attributed to the AT4-
receptor, including an increase of blood flow in various
vascular beds, antagonism of Ang II-induced hypertrophic
changes, and modulation of diastolic function. Moreover,
Ang IV has been shown to reverse endothelial dysfunction
[66].
Both ACE-inhibitors and angiotensin II receptor block-
ers (ARBs), by increasing Ang I availability, elevate Ang-
(1–7), which may contribute to the antihypertensive effects
of these drugs.
Blockade of the RAS would be expected to improve
endothelial function. There is a strong rationale for
blockade of the RAS early in the cardio–reno–vascular
continuum in order to prevent adverse events in patients
with cardio-vascular disease.
Murohara et al. have reported that the Ang II–AT1-
receptor pathway plays important roles in angiogenesis
associated with ischemia and tumor [68, 69]. Moreover,
Imanishi et al. have demonstrated that Ang II accelerates
EPC senescence by a gp91phox-mediated increase of
oxidative stress, resulting in EPCs dysfunction [70].
Spironolactone
In addition to its negative effects attributable to elevation of
the blood pressure, aldosterone has been suggested to
contribute to vascular damage by directly acting on the
vasculature. Moreover, aldosterone can cause swelling of
the endothelial cells and induce proinflammatory molecules
in peripheral blood mononuclear cells [71, 72]. More
recently, it has been demonstrated that aldosterone inhibits
the formation of bone marrow-derived progenitor cells, at
least partly, by attenuating VEGFR-2 expression and
subsequent Akt signaling and that this effect of aldosterone
was attenuated by cotreatment with spironolactone [73].
ACE-inhibitors
Although modulation of the RAS, by inhibition of ACE or
through blockage of Ang II type 1 receptors, reduces
mortality rates and major non-fatal cardiovascular events in
high-risk patients, [74], the underlying mechanisms behind
these beneficial effects have not been fully elucidated.
There is increasing evidence suggesting that one of the
pleiotropic effects of ACE-inhibitors on the cardiovascular
system involves modulation of the number and functional
activity of EPCs [75]. Moreover, this seems to be a class
effect since an improvement in EPC biology has been
demonstrated for several ACE-inhibitors (enalapril, ram-
ipril, perindopril, and quinapril).
Treatment with enalapril has shown to benefit neo-
vascularization in a murine hindlimb ischemia model. This
ACE-inhibitor seems to augment circulating EPC levels and
appears to influence EPCs through stimulating mobilization
rather than maturation. In response to ischemic stress,
enalapril, transiently and significantly increased the con-
centration of circulating SDF-1α but reduced its concen-
tration in the bone marrow, suggesting that reduced binding
of EPCs to SDF-1α in bone marrow may contribute to the
release and mobilization of EPCs after ACE-inhibitor
therapy [75]. The concentration gradient of plasma SDF-
1α between the bone marrow and the peripheral blood may,
at least in part, result from increased bone marrow activation
of dipeptidylpeptidase IV (DPP IV; CD26), a cell surface
endopeptidase that cleaves chemokines, such as SDF-1α
[75]. Thus, the beneficial effects of enalapril seem to be at
least in part due to its ability to alter the CD26/ DPP IV
system, and SDF-1α seems to be critical in the mechanism
through which enalapril modulates EPC mobilization [75].
Likewise, Min et al. have demonstrated that treatment
with ramipril for 4 weeks increased circulating EPCs levels
in patients with stable CAD [76]. Moreover, the increased
number of EPCs was paralleled by an enhancement of the
migratory, proliferative, adhesive, and in vitro vasculo-
genesis capacity of isolated EPCs [76]. In this work, the
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investigators suggested that the modulation of EPC kinetics
after the ramipril treatment was unrelated to the decrease in
blood pressure levels [76]. Moreover, as they observed that
ramipril increased NO levels, they speculated that the
activation of the bradykinin B2-receptor pathway by ACE-
inhibitors may contribute to the observed effects of ramipril
on the functional improvement of EPCs [76].
Another study demonstrated that the addition of quinap-
ril and metoprolol to EPC therapy induced neovasculariza-
tion and reduced the number of apoptotic cardiomyocytes.
However, the mechanisms by which this positive effect
occurred remain unclear [77].
Finally, perindopril is a long-acting ACE-inhibitor that
has been demonstrated to be able to increase the number of
circulating EPCs and to re-establish the ability of bone
marrow mononuclear cells to differentiate into EPCs in a
hindlimb ischemia model in spontaneously hypertensive
rats, either alone or in combination with indapamide [78].
In conclusion, there is mounting evidence that ACE
inhibition improves the biology of EPCs independently of a
vasodilator or hemodynamic effect. However, again, many
questions remain unsolved regarding the angiogenic effects
of these widely prescribed cardiovascular drugs: What is
the exact role of NO in ACE-inhibition-dependent vasculo-
genesis? Are all ACE-inhibitors equivalent regarding their
angiogenic action? Would the magnitude of EPC improve-
ment be similar in diabetic patients? What about other
conditions? Would ACE-inhibitors be able to improve
EPCs biology in patients with metabolic syndrome or heart
failure?
Angiotensin II receptor blockers
Blockade of AT1 receptors results in the inhibition of a
variety of deleterious effects. Furthermore, as circulating
Ang II increases during treatment with AT1 blockers, the
selective blockade of AT1 would be expected to result in
the stimulation of unblocked AT2-receptors, thereby en-
hancing AT2-mediated vasodilatation and antiproliferative
effects.
ARBs (olmesartan, irbesartan, losartan, candesartan,
telmisartan) have consistently been reported to increase
the number of EPCs [26, 79–82].
Bahlmann et al. demonstrated that Ang II subtype 1-
receptor blockage (with olmesartan or irbersartan) increased
the number of EPCs in patients with diabetes above that
found in healthy subjects and that this effect was
independent from their blood pressure-lowering action
[26]. Similarly, Chen et al. demonstrated that the combined
treatment with olmesartan and pravastatin increased the
number of circulating EPCs in a murine model of balloon
injury of the carotid arteries [79]. Additionally, studies in
spontaneously hypertensive rats have shown that losartan
and candesartan markedly increased the number and colony
formation of EPCs and exerted a favorable effect on EPC
migration, independently of their effects on blood pressure.
The authors of these published studies suggested that the
positive effects on EPC number and function are in part due
to an antioxidant effect [81, 82].
Similarly as for statins, the so-called pleiotropic effects
of ARBs are attracting the increasing interest in the
cardiovascular community, including their antidiabetic and
anti-inflammatory action [83, 84].
Some ARBs have also been shown to be selective
PPAR-γ modulators, implicating an involvement in the
metabolism, proliferation, and inflammation of cardiovas-
cular cells [85]. Telmisartan may be especially effective in
slowing down disease processes of the metabolic syndrome
on account of its effect on PPAR-γ [85]. It has recently
been demonstrated that telmisartan has a more potent anti-
inflammatory effect than ramipril after an acute coronary
syndrome. However, there are no differences between the
two drugs in terms of the magnitude of improvement on
EPC mobilization [80].
At the present time it is unknown whether the upregu-
lation of progenitor cells by ARBs is linked mechanistically
to the impact of these pharmacologic agents on endothelial
function or whether it is just a parallel effect. Therapy with
ARBs may provide a novel and effective therapeutic
strategy for the repair of vascular injury. However,
intracellular mechanisms involved in EPC stimulation by
ARBs have yet to be explored. Further studies are required
to determine the precise mechanisms of ARBs in modifying
the number and function of EPCs.
Antianginals: ß-blockers, calcium antagonists, and nitrates
Multiple experimental models and a number of randomized,
placebo-controlled, double-blind clinical trials have sug-
gested anti-atherosclerosis effects for all of these antiangi-
nal agents [86]. How these effects are related to
modification of EPC biology or to the documented
reduction in adverse outcomes in patients with myocardial
infarction, heart failure, or hypertension with ß-blockers is
not clear.
Calcium antagonists: dihydropyridine calcium channel
blockers
Most calcium antagonists have antioxidant effects and reduce
experimental inflammatory cell invasion. Dihydropyridine-
type calcium antagonists increase NO, block lipid peroxida-
tion, and may be associated with a reduction in cardiovascular
events [87].
Evidence that dihydropyridine calcium channel blockers
affect the functional activity of EPCs was initially obtained
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with benidipine in culture studies. Treatment of murine
mononuclear cells with this dihydropyridine calcium
channel blocker was shown to increase the number of early
EPCs after 7 days in culture, probably via the PI3K/Akt
signaling pathway [88]. Additionally, nisoldipine, another
L-type Ca2+ channel blocker, seems to induce the mobili-
zation of EPCs in patients with essential hypertension
independently of the blood pressure-lowering effect [89].
More recently, it has been demonstrated that nifedipine
also improves the functional capacity of EPCs. This
dihydropyridine calcium channel blocker enhances VEGF
release from EPCs and improves the migratory capacity of
cultured EPCs [90]. This study showed a nifedipine-
dependent upregulation of manganese superoxide dismu-
tase, which is known to confer resistance to oxidants,
suggesting a role of the antioxidant system for the effects of
nifedipine on EPCs [90].
It should be noted, however, that the majority of
favorable results with calcium antagonists have been
obtained from in vitro studies and that these need to be
confirmed clinically. In addition, one could question
whether these effects will persist in the context of
cardiovascular disease, such as acute coronary syndromes
and heart failure.
Beta blockers
It has recently been demonstrated that another group of
cardiovascular drugs improves EPCs number and function—
the beta blockers.
In spontaneously hypertensive rats, celiprolol has been
shown to increase the number of circulating EPCs and to
stimulate EPC colony formation and migration, while
decreasing EPC senescence. This beta blocker inhibited
oxidative stress in EPCs, suggesting that its beneficial effects
in EPCs are mediated by its antioxidative properties [91].
Further studies with other beta blockers are required to
determine if these benefits in EPC biology are exclusive of
celiprolol or a class effect of all beta blockers.
Nitrates
Nitrate compounds have been used in the treatment of
myocardial ischemia for more than 100 years. Their common
mechanism is the release of NO, which is a major regulator
of EPC mobilization, differentiation, and function [92].
Nevertheless, the majority of nitrates additionally stimulate
the production of ROS, a process that is partly involved in
the development of nitrate tolerance and may counteract the
beneficial effects of NO on the endothelium [93].
In a small clinical trial, nitroglycerine treatment of
healthy volunteers increased the level of circulating CD34
progenitor cells but also enhanced the susceptibility of
expanded EPCs to apoptosis [94]. Moreover, ex vivo
nitroglycerine exposure attenuated EPC differentiation,
function, and survival [94].
More recently, Thum et al. demonstrated that different
nitrates have a number of important effects on the
circulating levels and function of EPCs [95]. Therapy with
two different long-acting nitrates (nitroglycerine and
isosorbide-5-dinitrate) increased the levels of circulating
EPCs. However, functionally, there were strong differences
between the tested nitrates, with isosorbide-5-dinitrate
increasing ROS formation and impairing EPC function
and nitroglycerine having favorable effects even on EPC
function [95].
In one study, a considerable increase in oxidative stress
was observed after treatment with certain long-acting
nitrates, such as isosorbide-5-dinitrate [96]. In contrast,
treatment with nitroglycerine did not cause tolerance and
was not associated with evidence of increased ROS levels
[95, 96]. Thum et al. concluded that the differences
between the two studied long-acting nitrates in terms of
induction of oxidative stress in EPCs may explain their
differences in EPC biology [95].
In conclusion, further prospective studies are needed that
determine the long-term effects of organic nitrates on
number and function of EPCs.
Antiplatelet therapy: aspirin
Aspirin is widely used in the primary and secondary
prevention of vascular disease. It is a cornerstone of therapy
in acute coronary syndromes and has been shown to reduce
atherosclerosis-related events in a multitude of clinical
studies [97, 98]. Kharbanda et al. have reported a protective
effect of aspirin against endothelial dysfunction [99].
Surprisingly, in a study with healthy humans, Chen et al.
concluded that aspirin decreased the number of EPCs,
decreased the proliferative, migratory, adhesive, and in vitro
vasculogenesis capacity of EPCs, and decreased EPC
production of iNOS in a concentration- and time-dependent
manner [100]. However, recent in vivo observations have
suggested that low-dose aspirin promotes the migration
and adhesion and delays the onset of senescence of EPCs
[101].
These studies seem to be contradictory as they provide
evidence for both an inhibitory and a stimulating effect of
aspirin on EPC biology. Therefore, the effects of aspirin on
EPCs must be studied further.
Conclusion
Given the fact that EPCs contribute to postnatal neo-
vascularization, an improved understanding of the regula-
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tion of EPCs could lead to new insights into the
pathogenesis of vasculogenesis. Several cardiovascular
drugs, such as statins, ACE-inhibitors, ARBs, and beta
blockers have demonstrated a direct benefit on circulating
EPCs that may contribute to their overall effects on the
vascular wall. The augmentation of the number of EPCs
through pharmacological modulation of the signaling path-
ways may be a novel strategy to improve neovasculariza-
tion after ischemia and, thereby, provide a therapeutic
concept for improving the numbers of EPCs in patients
with cardiovascular diseases.
In conclusion, a more complete understanding of the
complex factors regulating EPC biology is required in order
to develop and investigate more focused clinical therapies.
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